Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biogen And Portola Target Arthritis

by Michael McCoy
October 31, 2011 | A version of this story appeared in Volume 89, Issue 44

Biogen Idec and Portola Pharmaceuticals will collaborate to develop Portola’s small-molecule Syk inhibitors for the treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. Biogen will provide Portola with $45 million up front and could make additional payments of up to $509 million. The collaboration’s lead molecule, PRT062607, is in Phase I studies. Biogen Idec’s product line today consists entirely of biologic drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.